SCHEMBL803689

SCHEMBL803689

COc1nc(C)cc(C(C)(C)C)n1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH4 Q9H3N8 1/20 0.50
HSD17B10 Q99714 2/20 0.40
KDM4E B2RXH2 1/20 0.36
MAPT P10636 3/20 0.34
LMNA P02545 2/20 0.34
KMT2A Q03164 2/20 0.34
MEN1 O00255 1/20 0.34
TSHR P16473 1/20 0.34
ATM Q13315 1/20 0.34
HSP90AA1 P07900 1/20 0.34
HSP90AB1 P08238 1/20 0.34
TP53 P04637 1/20 0.34
CYP3A4 P08684 1/20 0.34
HPGD P15428 1/20 0.34
ALOX15 P16050 1/20 0.34
ALDH1A1 P00352 3/20 0.34
SQOR Q9Y6N5 1/20 0.33
CA1 P00915 1/20 0.32
CA2 P00918 1/20 0.32
AURKA O14965 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17772772 0.82 HSD17B10 (0.56) HRH4HSD17B10KDM4EMAPTLMNA
SCHEMBL2629265 0.79 POLB (0.43) KDM4EMAPTLMNAKMT2AMEN1
SCHEMBL10220211 0.79 HRH4 (0.50) HRH4HSD17B10KDM4EMAPTLMNA
SCHEMBL24714028 0.78 HRH4 (0.49) HRH4HSD17B10KDM4EMAPTLMNA
SCHEMBL3308972 0.78 HRH4 (0.49) HRH4HSD17B10KDM4EMAPTLMNA
SCHEMBL25498235 0.78 HRH4 (0.35) HRH4
SCHEMBL31708020 0.77 HRH4 (0.33) HRH4HSD17B10
SCHEMBL25498082 0.75 CA1 (0.41) HRH4HSD17B10KDM4ELMNAKMT2A
SCHEMBL27114793 0.75 HRH4 (0.46) HRH4HSD17B10MAPTKMT2AMEN1
SCHEMBL803483 0.73 KDM4E (0.40) HRH4HSD17B10KDM4EMAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230149414-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-18 US disclosed
US-20230149414-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-18 US disclosed
US-8680159-B2 Bradykinin 1 receptor modulating compounds GRUENENTHAL GMBH (DE) 2014-03-25 US disclosed
US-20120071461-A1 Substituted Benzamide Compounds GRUENENTHAL GMBH (DE) 2012-03-22 US disclosed
US-20120071461-A1 Substituted Benzamide Compounds GRUENENTHAL GMBH (DE) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230149414-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB HRH4 3580/4885HSD17B10 1370/4885KDM4E 1848/4885
US-20120071461-A1 Substituted Benzamide Compounds BDKRB1, BDKRB2, HRH2 HRH4 5/4885HSD17B10 4316/4885KDM4E 2727/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.